Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Izanne Roos

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
BMJ Neurology Open|March 25, 2026
Neurological implications of chimeric antigen receptor-T cell therapyDaniel G Raffoul, Izanne Roos, Matthias Mulazzani, et al.
Multiple Sclerosis and Related Disorders|September 21, 2020
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in AustraliaNabil Seery, Vivien Li, Ai-Lan Nguyen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 27, 2024
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
CNS Drugs|April 13, 2021
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort StudyNabil Seery, Sifat Sharmin, Vivien Li, et al.
The Lancet. Child & Adolescent Health|March 28, 2024
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registriesSifat Sharmin, Izanne Roos, Charles B Malpas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2025
Disease course after pregnancy in women with progressive multiple sclerosis symptomsJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2024
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase RegistryAlessio Signori, Marta Ponzano, Tomas Kalincik, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 2026
Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansionDaniel Guilfoyle, Kayla Ward, Samuel Klistorner, et al.
Neurology|July 1, 2021
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisIzanne Roos, Emmanuelle Leray, Romain Casey, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
BMJ Neurology Open|March 25, 2026
Neurological implications of chimeric antigen receptor-T cell therapyDaniel G Raffoul, Izanne Roos, Matthias Mulazzani, et al.
Multiple Sclerosis and Related Disorders|September 21, 2020
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in AustraliaNabil Seery, Vivien Li, Ai-Lan Nguyen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 27, 2024
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
CNS Drugs|April 13, 2021
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort StudyNabil Seery, Sifat Sharmin, Vivien Li, et al.
The Lancet. Child & Adolescent Health|March 28, 2024
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registriesSifat Sharmin, Izanne Roos, Charles B Malpas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2025
Disease course after pregnancy in women with progressive multiple sclerosis symptomsJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2024
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase RegistryAlessio Signori, Marta Ponzano, Tomas Kalincik, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 2026
Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansionDaniel Guilfoyle, Kayla Ward, Samuel Klistorner, et al.
Neurology|July 1, 2021
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisIzanne Roos, Emmanuelle Leray, Romain Casey, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Pageof 8